West Pharmaceutical Services, Inc.
WST
$351.96
-$0.18-0.05%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.80% | 21.05% | 7.51% | 7.73% | 9.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.80% | 21.05% | 7.51% | 7.73% | 9.17% |
| Cost of Revenue | 10.25% | 17.68% | 5.45% | 5.83% | 4.34% |
| Gross Profit | 20.19% | 27.81% | 11.07% | 11.18% | 19.09% |
| SG&A Expenses | 18.52% | 14.90% | 29.05% | 23.44% | 13.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 400.00% | -833.33% | -- | -50.00% | -- |
| Total Operating Expenses | 11.51% | 16.21% | 9.32% | 8.38% | 5.92% |
| Operating Income | 22.50% | 42.42% | 1.40% | 5.46% | 23.55% |
| Income Before Tax | 14.94% | 61.11% | -0.90% | 3.33% | 21.62% |
| Income Tax Expenses | 6.62% | 85.48% | -9.51% | 4.94% | 37.90% |
| Earnings from Continuing Operations | 16.84% | 54.57% | 1.54% | 2.94% | 18.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.84% | 54.57% | 1.54% | 2.94% | 18.42% |
| EBIT | 22.50% | 42.42% | 1.40% | 5.46% | 23.55% |
| EBITDA | 20.26% | 35.45% | 4.09% | 5.75% | 19.60% |
| EPS Basic | 19.15% | 55.64% | 2.10% | 3.80% | 19.73% |
| Normalized Basic EPS | 23.15% | 41.31% | 2.82% | 6.65% | 25.25% |
| EPS Diluted | 18.13% | 56.10% | 2.08% | 3.78% | 20.53% |
| Normalized Diluted EPS | 22.80% | 41.49% | 3.10% | 6.94% | 25.92% |
| Average Basic Shares Outstanding | -1.94% | -0.69% | -0.55% | -0.82% | -1.10% |
| Average Diluted Shares Outstanding | -1.66% | -0.82% | -0.82% | -1.09% | -1.63% |
| Dividend Per Share | 4.76% | 4.76% | 4.76% | 5.00% | 5.00% |
| Payout Ratio | -0.11% | -0.33% | 0.02% | 0.01% | -0.13% |